drugset / Trial / NCT00199420

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

NCT00199420

Phase 3 Completed 580 enrolled Kyowa Kirin, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.

Timeline

Start
2004-07
Primary completion
2005-11
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 10 mg Oral
Subject Istradefylline Small molecule 20 mg Oral
Subject Istradefylline Small molecule 40 mg Oral

Indications